Both conditions are unsightly and can affect medication absorption
According to the results of the RCT for patients with monogenic obesity ( LEPR or POMC deficiency) and acquired hypothalamic obesity, setmelanotide can reduce body weight and inhibit appetite to a certain extent, and common adverse reactions include injection site reactions, skin hyperpigmentation, nausea, diarrhea, and abdominal pain, with occasional occurrences of sexual adverse reactions, depression, and suicidal ideation [51,52]
What did the Phase 2 trial show
Only 13 states provided coverage as of January 2026, down from 16 states in 2025, likely reflecting the significant costs of coverage and recent state budget challenges and federal funding cuts
Completing the intake does not guarantee a prescription
full results are pending